{"organizations": [], "uuid": "4cb1d14a0c5ba1b2f00a92090efba7a61807d126", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-jazz-pharmaceuticals-enrolls-first/brief-jazz-pharmaceuticals-enrolls-first-patient-in-clinical-trial-of-defibrotide-idUSASB0C79X", "country": "US", "domain_rank": 408, "title": "BRIEF-Jazz Pharmaceuticals Enrolls First Patient In Clinical Trial of Defibrotide", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-23T16:09:00.000+02:00", "replies_count": 0, "uuid": "4cb1d14a0c5ba1b2f00a92090efba7a61807d126"}, "author": "", "url": "https://www.reuters.com/article/brief-jazz-pharmaceuticals-enrolls-first/brief-jazz-pharmaceuticals-enrolls-first-patient-in-clinical-trial-of-defibrotide-idUSASB0C79X", "ord_in_thread": 0, "title": "BRIEF-Jazz Pharmaceuticals Enrolls First Patient In Clinical Trial of Defibrotide", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-jazz pharmaceuticals enrolls first patien", "sentiment": "negative"}, {"name": "clinical trial of defibrotide reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "jazz pharmaceuticals plc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 23, 2018 / 2:10 PM / Updated 10 minutes ago BRIEF-Jazz Pharmaceuticals Enrolls First Patient In Clinical Trial of Defibrotide Reuters Staff 1 Min Read Feb 23 (Reuters) - Jazz Pharmaceuticals Plc: * JAZZ PHARMACEUTICALS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL EVALUATING DEFIBROTIDE FOR THE PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-23T16:09:00.000+02:00", "crawled": "2018-02-23T16:23:09.001+02:00", "highlightTitle": ""}